Our peptide manufacturing facility at Changzhou site has successfully passed the Pre-Approval Inspection by Japan Pharmaceuticals and Medical Devices Agency (PMDA) for an innovative peptide drug. The 3-day inspection, without any major findings, highlighted our commitment to quality and excellence in peptide production.
Since January 2024, we’ve tripled our solid-phase peptide synthesis capacity to more than 32,000 L across our Changzhou and Taixing sites, and more capacities will be added in Taixing and Singapore to accelerate peptide drugs to patients.
